TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Nasogastric Tube in Premature Babies - Pain and Treatment. A Randomised, Partly Blinded, Placebo-controlled Factorial Clinical Trial of Sucrose and Pacifier
Brief Summary: Does sucrose or pacifier influence pain in premature babies when a nasogastric tube is inserted?


Options:
A: Inclusion Criteria:

* 28 - 32 weeks gestational weeks
* not on mechanical ventilation

Exclusion Criteria:

* high risk group regarding cerebral prognosis
B: Inclusion Criteria:

* Healthy infant
* 2 - 6 months of age
* receiving primary DPT and PCV vaccinations

Exclusion Criteria:

* chronic illness
* immune deficiency
* immunosuppression
* a history of allergy to DPT or PCV or any of its components
* fever
* any acute illness that prevents the administration of the vaccine
C: Inclusion Criteria:

* Children aged between 2 and 8 years of American Society of Anesthesiologists physical status (ASA PS) I or II who are planned to receive ophthalmology or otorhinolaryngology surgery under general anesthesia

Exclusion Criteria:

* ASA PS III or IV
* with developmental delay or neurological diseases associated with symptoms of agitation
* refusal of consent
* maternal mutism
* absence of mother
* with allergy or contraindication to use of ketamine (increased intracranial pressure, open-globe injury, and a psychiatric or seizure disorder)
D: Inclusion Criteria:

* unilateral inguinal hernia
* age age \> 4 months, \<16 years
* fully descended testes
* study consent signed

Exclusion Criteria:

* previous abdominal or inguinal surgery
* testes not fully descended
* not healthy enough for day surgery
* age \< 4months or \>16 years
* study consent not signed

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees and Asylum Seekers in Mid-Norway
Brief Summary: In this study we want to compare Narrative Exposure Therapy to Treatment as Usual for traumatized refugees and asylum seekers in the Mid- Norway region. Clinicians in psychiatric outpatient clinics will deliver the two conditions to asylum seekers and refugees that qualifies for Posttraumatic Stress Disorder. We will investigate if refugees and asylum seekers will improve more with Narrative Exposure Therapy or Treatment as Usual, and if there will be any differences between improvement for asylum seekers compared to improvement for refugees with residential status.


Options:
A: Inclusion Criteria:

* Refugee or asylum seeker
* Posttraumatic Stress Disorder diagnosis according to the DSM-IV criteria

Exclusion Criteria:

* Psychosis
* Substance abuse
* Serious suicidal ideations
B: Inclusion Criteria:

* survivor of sexual violence
* mental health symptom severity cut-off
* functional impairment cut-off

Exclusion Criteria:

* active suicidality
* not living in the study site
C: Inclusion Criteria:

* Patients referred to treatment in Psychiatric Clinic for refugees, Psychiatric Center Ballerup between April 2012 to May 2013
* Adults (18 years or older)
* Refugees or reunified with a refugee spouse
* Symptoms of PTSD defined by ICD-10 research criterias.
* Previosly traumatized
* Motivated for treatment
* Informed consent

Exclusion Criteria:

* Psychotic disorder (ICD-10 diagnosis F2x og F30.1-F309)
* Active substance abuse (ICD-10 F1x.24-F1x.26).
* In need of acute admission to psychiatric hospital)
* No informed consent
* Pregnant women, breastfeeding women or women who wish to become pregnant within the project period.
D: Inclusion Criteria:

* experiences of organized violence/torture
* PTSD diagnosis

Exclusion Criteria:

* psychotic disorder
* neurological disease or seizures
* current drug/alcohol abuse

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effective Endurance Training in Metabolic Syndrome
Brief Summary: To see how fast and how much physical training can reduce risk factors related to metabolic syndrome


Options:
A: 1. Subjects with NAFLD determined by MRS ;
2. Age 40-65 years old;
3. Waist circumference\> 90cm for men and \> 85cm for women.
B: Inclusion Criteria:

* insulin resistance, impaired glucose tolerance or type 2-diabetes, including two or more of the following factors: Blood pressure ≥ 140/90 mm Hg, Triglycerides Fasting ≥ 1,7 mmol/l, and/or low HDL-cholesterol (≤ 0,9 mmol/l in men, ≤ 1,0 mmol/l in women)
* Obesity, Waist-hip ratio ≥ 0,9 in men, ≥ 0,85 in women or BMI (body mass index) ≥ 30 kg/m2
* Microalbuminuria (albumin secretion ≥ 20 mg/l or 20 - 200 g per minute)

Exclusion Criteria:

-
C: Inclusion Criteria:

* Age 40 years and older
* Diabetes mellitus
* Peripheral arterial disease
* Leg symptoms

Exclusion Criteria:

* Myocardial infarction within 3 months of enrollment
* Inability to walk for exercise secondary to chest pain, dyspnea, or poor balance
* Prior major amputation
D: Inclusion Criteria:

\* Adults users of 4 Primary Health Care Centers in Catalunya.

Exclusion Criteria:

* Previous episode of ischemic heart disease (\<6 months).
* Outbreak of arthritis with limited ability to ambulate.
* Lung or heart disease with dyspnea mild-moderate efforts.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Inclusion Criteria:

-Patients with essential hypertension

Exclusion Criteria:

* Severe hypertension
* History or evidence of a secondary form of hypertension
* History of myocardial infarction. Other protocol-defined inclusion exclusion criteria also apply
B: Men and women hypertensive patients, ages 55 and above. A total of 36 percent were diabetics.
C: Inclusion Criteria:

* Age 55 to 80 years
* Males and females
* Hypertension (160-200/95-115 mm Hg
* ECG evidence of left ventricular hypertrophy

Exclusion Criteria:

* Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers
* Myocardial infarction or stroke within 6 months
D: * not taking anti-hypertensive medication
* use of anti-hypertensives for less than two months with a baseline blood pressure between 140/90 and 180/110
* use of anti-hypertensives for greater than two months with a blood pressure not greater than 160/100
* at least one additional cardiovascular risk factor such as previous MI, stroke, type 2 diabetes, smoking, left ventricular hypertrophy or dyslipidemia

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Inclusion Criteria:

* Patients with essential hypertension

Exclusion Criteria:

* Severe hypertension
* History or evidence of a secondary form of hypertension
* History of myocardial infarction.
* Other protocol-defined inclusion exclusion criteria also apply.
B: Inclusion Criteria:

* Clinical diagnosis of hypertension, ischemic heart disease and congestive heart failure

Exclusion Criteria:

* Pregnancy
* Severe renal damage
* Severe liver damage
* Acute myocardial infarction
C: Inclusion Criteria:

* Adults
* Impaired glucose tolerance
* Age dependent risk factors

Exclusion Criteria:

* Frank diabetes

For detailed information, call contact person.
D: Inclusion Criteria:

-Patients with essential hypertension

Exclusion Criteria:

* Severe hypertension
* History or evidence of a secondary form of hypertension
* History of myocardial infarction. Other protocol-defined inclusion exclusion criteria also apply

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
Brief Summary: This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.


Options:
A: Inclusion Criteria:

-Patients with essential hypertension

Exclusion Criteria:

* Severe hypertension
* History or evidence of a secondary form of hypertension
* History of myocardial infarction. Other protocol-defined inclusion exclusion criteria also apply
B: Inclusion Criteria

* Patients with essential hypertension
* Patients who are eligible and able to participate in the study

Exclusion Criteria

* Severe hypertension
* History or evidence of a secondary form of hypertension
* History of Hypertensive encephalopathy or cerebrovascular accident

Other protocol-defined exclusion criteria may apply.
C: Inclusion Criteria:

* Patients with CAD who have blood pressure in the pre-hypertensive range defined as a msSBP ≥ 125 and ≤ 139mmHg and a msDBP \< 90mmHg.
* Patients with or without current treatment for hypertension
* Angiographic evidence of coronary artery disease
* At least 2 qualifying Cardiovascular risk factors at Visit 1

Exclusion Criteria:

* Baseline IVUS determined unacceptable
* Patients requiring treatment with disallowed study medications
* Patients with clinically significant heart disease
* Previous or current diagnosis of heart failure (NYHA Class IV) or a documented left ventricular ejection fraction of \< 25%
* Patients requiring treatment with any 2 of the following classes of medication at Visit 1 or Visit 2:

  * Angiotensin converting enzyme inhibitors
  * Angiotensin receptor blockers
  * aldosterone receptor blockers or a direct renin inhibitor.
* Other conditions may apply
D: Inclusion Criteria:

* Patients with essential hypertension

Exclusion Criteria:

* Severe hypertension
* History or evidence of a secondary form of hypertension
* History of myocardial infarction.
* Other protocol-defined inclusion exclusion criteria also apply.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Diabetic Cardiovascular Complications With Vitamin E 400 IU Treatment to High Risk Patients by Haptoglobin Phenotype (I CARE - Israel Cardiovascular Atherosclerosis Risk and Vitamin E)
Brief Summary: The purpose of this study is to determine whether Vitamin E treatment to Diabetic patients, who carry the Haptoglobin 2-2 Phenotype, prevents cardiovascular complications such as acute MI and Stroke.


Options:
A: Inclusion Criteria:

* Diabetic patients aged 55 and above

Exclusion Criteria:

* Patient who takes antioxidant treatment will be asked to stop, or can't be included in the study
* Patients who had a CVD incident (MI, Stroke, TIA), Unstable angina pectoris, Uncontrolled HTN, will have to wait a month after stabilization to be included in the study
* Allergy to Vitamin E
B: Inclusion Criteria:

* women aged 35-60 years, men aged 45-60 years
* acceptance of the possibility to be given a placebo and acceptance of the constraints of participation
* lack of previous regular supplementation with any of the vitamins or minerals in the supplement provided
* absence of extreme beliefs or behavior regarding diet

Exclusion Criteria:

* disease likely to hinder active participation or threatened 5-year survival
C: Women, aged 40 and over, at high risk, with a history of cardiovascular disease or three or more coronary heart disease risk factors.
D: * INCLUSION CRITERIA:

Participants will be eligible if they:

* Were enrolled in the AREDS or AREDS2 protocol and successfully completed the final AREDS or AREDS2 follow-up visit.
* Can understand and provide informed consent.

EXCLUSION CRITERIA:

Participants will not be eligible if they:

* Are under the age of 50.
* Are not able to return to NIH for examination for the duration of the trial.
* Have any systemic diseases that compromise the ability to provide adequate ophthalmologic examination.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Trachoma Elimination With Repeated Mass Azithromycin Treatments
Brief Summary: The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. It is not clear how frequently or for how long these treatments are necessary. Here we assess the frequency and duration of treatment.


Options:
A: Inclusion Criteria:

Age 1 to 5 years old in a village in the Gurage zone with endemic trachoma

Exclusion Criteria:

Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)
B: Inclusion criteria for communities:

* Communities are located in the target districts and accessible by vehicle
* The community leaders consent to have the community enrolled
* Rapid assessment and/or available data suggest trachoma rates are higher than 20% in the community.
* The community size is \<5,000 persons or \>250 persons.

If a community meets the inclusion criteria and community leaders consent to have the community enrolled, then sentinel children will be selected based on the following criteria:

* The child is age 5 years or younger
* The child must be a resident in an eligible, sample community (defined as either living in the community since birth, or moved in with parents or guardians).
* The child must not have an ocular condition that would preclude grading trachoma or taking an ocular specimen.
* The child must be willing to have a swab taken as part of being a sentinel child (this is critical for The Gambia and Tanzania, as each swab result counts towards meeting the stopping rule)
* The child must have an identifiable guardian capable of providing consent to participate.
C: Inclusion Criteria:

Communities

* The community location in target district.
* The community leader consents to participation in the trial
* The community's estimated population is between 200-2,000 people.
* The community is not in an urban area.

Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census.

Exclusion Criteria:

Individuals

- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)
D: Inclusion Criteria:

* Must have been residing in the village for at least three months;
* Must be 90 cm tall or more;
* Must be between 5 years and 65 years of age;
* Must not be pregnant;
* Must not be lactating.

Exclusion Criteria:

* Subjects under 5 years of age or less than 90 cm in height;
* Subjects over 65 years of age;
* Subjects who cannot swallow tablets;
* Subjects who are sick and bedridden;
* Pregnant women (clinical appreciation in the study);
* Lactating women;
* History of allergies to the drugs being studied (azithromycin, ivermectin, albendazole).

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Increasing Infant Preventive Health Service Delivery in an Inner City Population
Brief Summary: The study hypothesis is that case management using patient navigators ("promatoras" in the Latino community) will increase infant immunization rates and use of well child care in an inner city population of low socioeconomic status.


Options:
A: Inclusion Criteria:

* child between the age of 19-35 months
* has an address in a specified study county in the state immunization registry
* child is in need of at least one recommended immunization

Exclusion Criteria:

* child has opted out of the state immunization registry
* child is up-to-date on all recommended immunizations
B: Inclusion Criteria:

* Any child born at Denver Health Medical Center between 2/1/04 and 1/31/05 who receives primary care at one of 3 community health centers.

Exclusion Criteria:

* No medical care in the Denver Health community health system after 42 days of age.
* Birthweight less than 1500 grams.
C: Inclusion Criteria:

* Infants 1-3 months of age coming for their 1 dose of primary vaccines

Exclusion Criteria:

* Received 1 dose of vaccines, excluding BCG
* No mobile phone with SMS or unable to use SMS at home
* Intent to move from the clinic area in the next 6 months
D: Inclusion Criteria:

* children, 24-60 months
* current or previous enrollment in Medicaid (Michigan)
* presence of at least 1 chronic condition, as indicated by the Michigan Care Improvement Registry (MCIR)
* resident of Kalamazoo, Ottawa, or Kent counties (Michigan)

Exclusion Criteria:

* receipt of influenza prior to notification date
* ineligible for reminder/recall notification in the Michigan Care Improvement Registry (MCIR)

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Increasing Infant Preventive Health Service Delivery in an Inner City Population
Brief Summary: The study hypothesis is that case management using patient navigators ("promatoras" in the Latino community) will increase infant immunization rates and use of well child care in an inner city population of low socioeconomic status.


Options:
A: Inclusion Criteria:

* Any child born at Denver Health Medical Center between 2/1/04 and 1/31/05 who receives primary care at one of 3 community health centers.

Exclusion Criteria:

* No medical care in the Denver Health community health system after 42 days of age.
* Birthweight less than 1500 grams.
B: Inclusion Criteria:

A household will be defined as vulnerable and thereby eligible for inclusion in the programme if there are children \<18 years resident in the household at baseline AND

* household is in the poorest quintile of households (20%) at baseline OR
* household contains one or more orphans at baseline OR
* the household head is under 18 years of age at baseline OR
* household contains a chronically ill member OR
* household contains a disabled member

A household will be defined as individuals that live within the same homestead and eat from the same pot.

Exclusion Criteria:

Households already receiving cash transfers for orphans or vulnerable children (OVC) will not be eligible to enroll in the pilot programme.

During the trial, households that do not qualify at baseline but whose conditions later change such that they become eligible to participate in the pilot will not be able to enroll.
C: Inclusion Criteria:

* Gram panchayats in Uttar Pradesh
D: Inclusion Criteria:

* 7 and 19 month recall groups: children not up to date for at least one vaccination at the time of notification
* 12 month reminder group: 12 months of age at time of notification
* Hib vaccination series was not assessed due to a vaccine shortage

Exclusion Criteria:

* Children were ineligible for notifications if they were designated in the Michigan Care Improvement Registry (MCIR)as having died, documented previously as having moved out of the jurisdiction ("Moved or Gone Elsewhere" (MOGE)), opted out of MCIR by their parent, or if they had been previously mailed for MCIR reminder/recall activity in the prior 60 days.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Can Early Intervention Prevent Developmental Disturbances/Delays and Improve the Health of Children Born Prematurely
Brief Summary: The purpose of this study is to examine whether an early intervention program may improve cognitive and behavioral short and longterm outcome in preterm infants.


Options:
A: Inclusion Criteria:

* Infant is born a singleton or twin in the Morgan Stanley Children's Hospital in New York City
* Infant is born 26 and 34 weeks post-conceptional age (PCA)

Exclusion Criteria:

* Mothers cannot understand or speak English
* Mother has history of drug addiction, psychosis or other severe mental illness
* There is not at least one adult other than the mother in the home
* Infant birth weight is below the third percentile for gestational age
* Infant has significant congenital defects
B: Inclusion Criteria:

* Birth weight \< 2000 gram

Exclusion Criteria:

* Congenital anomalies
* Non-Norwegian speaking mother
* Triplets
C: Inclusion Criteria:

* Premature infants between 34 and 37 weeks of gestation,
* Infants with weight over 1800gr
* Hemodynamic stability
* Interns in NICU of participants institutions (Colombia and Poland).
* Infants with residence in a places close to the institutional health care services.

Exclusion Criteria:

* Premature child with a musculoskeletal deformity.
* Premature child with diagnosis of a genetic syndrome
* Premature child with congenital heart diseases.
* Premature child with brain injuries.
D: Inclusion Criteria:

* extremely premature born babies
* close to discharge from their neonatal intensive care unit hospital stay at Stockholm county council (Stockholms Läns Landsting).

Exclusion Criteria:

* Children with parent/parents who do not communicate in Swedish or English.
* Patients not residing in Stockholm county.
* Acute surgery patients who will spend a lot of time at hospitals far from Stockholm

Answer: B